Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

Our results highlight a complex, time-dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1-ALS and beyond. ANN NEUROL 2025;98:1318-1334.

Authors

Institutions

Publication Details

Journal
Annals of Neurology
Published
2025-08-09
DOI
https://doi.org/10.1002/ana.70025
Citations
5
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
6.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

René Günther, Maximilian Vidovic, Dávid Brenner, Thomas Haarmeier et al.
5 citations
Annals of Neurology
Amyotrophic Lateral Sclerosis Research
6.95
article

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

René Günther, Maximilian Vidovic, Dávid Brenner, Thomas Haarmeier, Peter Reilich, Patrick Weydt, Alberto Catanese, Tim Hagenacker, Simon Witzel, Patrick Oeckl, Paul Lingor, Željko Uzelac, Maximilian Wiesenfarth, Joachim Schuster, Andreas Hermann, Jochen Hans Weishaupt, Hayrettin Tumani, Zeynep Elmas, Ritchie Ho, Johannes Prudlo, Kornelia Günther, Alexander German, Wolfgang Ruf, Ute Weyen, Julian Großkreutz, Antje Knehr, Martin Regensburger, Axel Freischmidt, Franziska Bachhuber, Thomas Meyer, Christina Steffke, Karthik Baskar, Susanne Petri, Albert C. Ludolph, Johannes Dorst, Florian Schöberl, Joachim Wolf
article en
5 citations

Abstract

Our results highlight a complex, time-dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1-ALS and beyond. ANN NEUROL 2025;98:1318-1334.

Annals of NeurologyVol. 98(6)
Cedars-Sinai Medical Center (US), University of Bonn (DE), University of Freiburg (DE), University of Mannheim (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universität Ulm (DE), Heidelberg University (DE), German Center for Neurodegenerative Diseases (DE), University Hospital Heidelberg (DE), TUM Klinikum (DE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Institute of Pathology Celle (DE), Helios Klinikum Krefeld (DE), Munich Cluster for Systems Neurology (DE), Essen University Hospital (DE), Diakonissenkrankenhaus (DE), Friedrich Baur Stiftung (DE), BG University Hospital Bergmannsheil Bochum (DE), University Hospital Ulm (DE), University Hospital Carl Gustav Carus (DE), Technische Hochschule Ulm (DE), University of Rostock (DE), Ludwig-Maximilians-Universität München (DE), Ruhr University Bochum (DE), University of Lübeck (DE)
Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung, Deutsche Gesellschaft für Muskelkranke
Openalex Percentile: Top 3%
Amyotrophic Lateral Sclerosis Research
6.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.